- Home
- OI vs APLS Comparison
OI vs APLS Comparison
Compare OI & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OI
- APLS
- Stock Information
- Founded
- OI 1903
- APLS 2009
- Country
- OI United States
- APLS United States
- Employees
- OI N/A
- APLS N/A
- Industry
- OI Containers/Packaging
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- OI Consumer Discretionary
- APLS Health Care
- Exchange
- OI Nasdaq
- APLS Nasdaq
- Market Cap
- OI 2.2B
- APLS 2.2B
- IPO Year
- OI N/A
- APLS 2017
- Fundamental
- Price
- OI $14.29
- APLS $19.31
- Analyst Decision
- OI Buy
- APLS Buy
- Analyst Count
- OI 8
- APLS 19
- Target Price
- OI $17.00
- APLS $37.61
- AVG Volume (30 Days)
- OI 2.0M
- APLS 1.9M
- Earning Date
- OI 07-29-2025
- APLS 07-31-2025
- Dividend Yield
- OI N/A
- APLS N/A
- EPS Growth
- OI N/A
- APLS N/A
- EPS
- OI N/A
- APLS N/A
- Revenue
- OI $6,505,000,000.00
- APLS $775,839,000.00
- Revenue This Year
- OI $2.05
- APLS $8.00
- Revenue Next Year
- OI $1.35
- APLS $13.82
- P/E Ratio
- OI N/A
- APLS N/A
- Revenue Growth
- OI N/A
- APLS 48.04
- 52 Week Low
- OI $9.23
- APLS $16.10
- 52 Week High
- OI $16.04
- APLS $41.94
- Technical
- Relative Strength Index (RSI)
- OI 45.01
- APLS 62.16
- Support Level
- OI $14.20
- APLS $19.13
- Resistance Level
- OI $14.63
- APLS $20.61
- Average True Range (ATR)
- OI 0.43
- APLS 0.79
- MACD
- OI -0.20
- APLS 0.22
- Stochastic Oscillator
- OI 6.79
- APLS 87.50
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.